Brief: Bio-Path Holdings Announces Positive Results From Interim Analysis Of Phase 2 Clinical Trial Of Prexigebersen In Acute Myeloid Leukemia
01/08/2023 12:14
Aug 1 (Reuters) - Bio Path Holdings Inc BPTH.O :
* BIO-PATH HOLDINGS ANNOUNCES POSITIVE RESULTS FROM INTERIM
ANALYSIS OF PHASE 2 CLINICAL TRIAL OF PREXIGEBERSEN IN ACUTE
MYELOID LEUKEMIA
* BIO PATH HOLDINGS INC - PREXIGEBERSEN CONTINUES TO BE
WELL-TOLERATED AND HAS NOW SHOWN COMPELLING EFFICACY RESULTS IN
TWO REPORTING COHORTS
* BIO PATH HOLDINGS INC - PROTOCOL FOR PHASE 2 STUDY ALLOWS
BIO-PATH TO CONDUCT AN INTERIM EFFICACY ANALYSIS ON EACH COHORT
AT ITS DISCRETION
Source text for Eikon: ID:nGNXbgKzbh
Further company coverage: BPTH.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Bio Path Holdings
See all newsBrief: Bio-Path Holdings Seeks Financing For Turnaround & Strategic Actions
Brief: Bio-Path Holdings Reports Full Year 2024 Financial Results
Brief: Bio-Path Holdings Announces Pre-Clinical Results Signaling Increased Potential for BP1001-A as Treatment for Obesity in Type 2 Diabetes Patients
Brief: Bio-Path Provides Key Clinical Updates
Brief: Bio-Path Holdings Provides Update From Phase 1/1B Clinical Trial Of Bp1002 For Treatment Of Refractory/Relapsed Acute Myeloid Leukemia